Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial
Brief Summary: In patients with schizophrenia, 'atypical' antipsychotics such as clozapine may be effective in the treatment of psychosis. In patients with borderline personality disorder (BPD), as far as the investigators know, no well designed controlled studies have been performed on the effect of one of the newer atypical antipsychotics on psychotic symptoms.

It is of interest to investigate the benefit of quetiapine treatment in these types of patients. Quetiapine possibly gives less side-effects because of the expected lack of elevated prolactin levels, which is of importance in this patient group, overrepresented by young females. In this double blind, randomized, placebo controlled, 8 week, parallel group, multi-center study, quetiapine (in flexible doses between 200 mg/day and 600 mg/day) will be compared with the placebo.


Options:
A: Inclusion Criteria:

* French speaking patients freely hospitalized for prevention of suicide and who have a medium or high suicide risk score according to a MINI structured interview
* The patient is able to understand how the study is carried out and the tests performed
* The patient is deemed capable of giving his/her informed consent
* The patient has been correctly informed
* The patient must have given his/her informed and signed consent.
* The patient must be insured or beneficiary of a health insurance plan.
* Presence of suicidal ideation according to the SSI score (score \> 3)
* Negative pregnancy test for women of childbearing age

Exclusion Criteria:

* The patient is participating in another interventional study
* Within the past three months, the patient has participated in another interventional study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection
* The patient is an adult under guardianship
* The patient refuses to sign the consent
* The patient is not able to understand the informed consent
* Pregnancy or breastfeeding
* History of schizophrenia or other psychotic disorders
* Presence of psychotic symptoms at initial interview
* Schizoid or schizotypic personality disorder
* Positive urine screening for illicit substances, excluding cannabis
* Substance dependence in the preceding month (excluding nicotine or caffeine)
* Concomitant treatment with electroconvulsive therapy
* Unstable somatic pathology
* Clinically significant anomalies found during clinical examination, biological test or ECG
* Non-stabilized hypertension or hypertension \> 180/100
* Known or suspected contra-indication for ketamine (includes interactions): hypersensitivity to ketamine, hypertension, class IV cardiac insufficiency, history of stroke, hepatic or cutaneous porphyria, history of intracranial hypertension
B: Inclusion Criteria:

* Patients with BPD according to Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV)/Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) including criterion 9: transient, stress related paranoid ideation or severe dissociative symptoms.
* In- or outpatients

Exclusion Criteria:

* Depressive disorder
* Bipolar disorder
* Schizoaffective disorder/schizophrenia/delusional disorder/schizotypal personality disorder
* Alcohol- or substance dependence
* Quetiapine doses \>100mg od use in the past

Somatic:

* History of trauma capitis
* Visual and auditive disorders
* Neurological disorders (epilepsy)
* Pregnancy
* No adequate contraception
* History of cardial complaints/cardiological disorder
* Known sensitivity for quetiapine
C: Inclusion Criteria:

* Diagnosis of AD
* Diagnosis of BPD

Exclusion Criteria:

* Serious or unstable medical condition
* Opiate dependence
* Major Axis I disorder (bipolar disorder, schizophrenia)
* Taking mood stabilizers and antipsychotic medications
* LFT abnormalities that do not exceed 3 times normal values
D: General Inclusion Criteria:

* Female and males, age \>= 12 years
* Having attended a hospital emergency department due to a suicide attempt
* Willing and able to comply with study procedures and to give written informed consent

Specific inclusion criteria for iFD-S:

* Minimum knowledge of internet use and availability of an internet device (tablet, computer, smartphone)
* Depressive symptoms according to PHQ-9 scores above 15

Specific inclusion criteria for SAM:

* Age between 12-17
* Informed consent of legal guardians

General Exclusion Criteria:

* Incapacity to give informed consent
* Lack of fluency in Spanish
* Currently taking part in another clinical study which, in the opinion of the investigator, is likely to interfere with the objectives of the SURVIVE study.

Answer: B